Adamis Pharmaceuticals Corp (ADMP)

[66Mustang]

“An oral drug that prevents SARS-CoV-2 from replicating would be an important tool for reducing the severity of the disease.”

This sounds to me like an endorsement, just not one which calls out Tempol specifically yet. The NIH info over the past couple weeks certainly indicates that Tempol appears to meet this criteria, so in combination, I think the word "endorse" is applicable. Bear in mind, the quote is from the NICHD, not the NIH directly, but NICHD does fall under the NIH umbrella.



Message in reply to:
Endorsed? This is simply not accurate and not the position the NIH took. Some of their words...

"may be a promising"

"we are hopeful"

"clinical studies are needed to determine if the drug is effective in patients, particularly early in the disease course when the virus begins to replicate"

Saying that the NIH "endorsed" is misleading!